Insulin glargine biosimilar - Samsung Bioepis/Merck & Co.

Drug Profile

Insulin glargine biosimilar - Samsung Bioepis/Merck & Co.

Alternative Names: Lusduna; LUSDUNA Nexvue; MK 1293; SB 9

Latest Information Update: 24 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Samsung Bioepis
  • Developer Merck & Co; Samsung Bioepis
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Insulin receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Diabetes mellitus
  • Preregistration Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 20 Jul 2017 FDA issues tentative approval to insulin glargine biosimilar for Type-1 diabetes mellitus and Type-2 diabetes mellitus in USA
  • 04 Jan 2017 Registered for Diabetes mellitus in European Union, Iceland, Norway, Liechtenstein (SC)
  • 16 Sep 2016 Sanofi files a patent infringement suit against Merck Sharp & Dohme in the US District Court for the District of Delaware
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top